Amniotic Membrane Market

Amniotic Membrane Dressings Reduce Infection Transfer in Burn Patients

Chronic burn wounds lead to trauma amongst patients. What adds to the patient’s difficulty is the risk of infection, sepsis, joint problems, and scarring during the management of third-degree burns. Hence, healthcare industries are increasing awareness about amniotic membranes (AM), since these membranes have gained the approval of many health commissions across various countries.

Healthcare providers in the amniotic membrane market are increasingly using fresh amniotic membranes as dressings on burn areas. It has been found that, serology and virology tests validate the use of frozen amnion membrane dressings to minimize the risks of infection transfer. Companies in the amniotic membrane market are increasing the availability of amnion membranes to facilitate the reepithelization of burn wounds. Incremental opportunities related to burn wounds are likely to grow, since the overall surgical wounds domain accounts for the highest revenue amongst all applications in the amniotic membrane market, with a predicted value of ~US$ 1.2 billion by 2027.

The growing trend of amniotic membranes enriched with stem cells is gaining traction in the healthcare landscape. This trend is anticipated to grow even further, since it has been found that, amniotic membrane dressings significantly reduce pain in burn patients.

To know the scope of our report Get a Sample on Amniotic Membrane Market

Companies Innovate in Stem Cell-induced hAM for Cardiac Tissue Regeneration

There is growing demand for human amniotic membranes (hAM) for cardiac tissue regeneration. Hence, healthcare companies in the amniotic membrane market fostering innovation in human-induced pluripotent stem cell (hiPSC)-derived cardiac muscle cells for successful cardiac tissue regeneration. This technique is pervasively becoming a treatment alternative to gelatin-based 3D matrix matrigel protein.

Heart attacks can lead to necrosis of the cardiac tissue. This trend has become a driver for the amniotic membrane market, since increasing rates of heart failures have led to several deaths, worldwide. Individuals are becoming increasingly aware about hAM. Hence, companies in the amniotic membrane market are increasing the availability of hAM in hospitals and ambulatory surgical centers to aid successful regeneration of injured cardiac tissue.

Healthcare companies are focusing on innovation regarding the combination of stem cells and synthetic materials for cardiac tissue regeneration. Decellularized biological matrices are also emerging as a useful alternative for tissue regeneration.

Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain

Foot pain is one of the most common orthopedic complaints in the healthcare landscape. To cater to this prevalent health condition, healthcare industries are developing improved amniotic allografts to reduce joint and soft tissue pain. The introduction of amniotic allografts has helped reduce pain and enhance healing in patients suffering from foot and ankle pain.

Growing incidence of repeated trauma and joint pain in the feet has triggered the demand for amniotic allografts. Healthcare providers are providing relief to patients after several clinical trials through musculoskeletal ultrasound, electromyography and computerized tomography scans. Amniotic allografts are becoming increasingly popular amongst patients, since this technique provides long-term relief, unlike the conventional non-operative management of joint pain.

Get a glimpse of the in-depth analysis through our Report Brochure

Locally available amnion mesenchymal cell injections are creating incremental opportunities for healthcare companies, since these injections help in the healing of injured peripheral nerves.

HAAM-based Approach Becomes Increasingly Suitable for Treatment of Skin Wounds

The lower third of the nose is one of the most important cosmetic units as far as the face is concerned. However, reconstruction techniques for the same remain a challenge for healthcare industries in the amniotic membrane space.

Human acellular amniotic membrane (HAAM) implantation serves as an effective approach for lower third nasal reconstruction. Companies in the amniotic membrane market are carrying out extensive investigations to closely study this biomaterial-based strategy. However, in many cases, HAAM leads to full-thickness defects after the surgical procedure. Lack of research studies make it unclear whether the locations of the wound affect the healing potential of HAAM. To overcome these challenges, healthcare industries in the amniotic membrane market are increasing efforts to establish a standardized process for HAAM that can aid its adoption for future clinical use.

Altogether, HAAM is found to have a promising approach for treating various skin defects. Hence, healthcare industries are increasing its application in the amniotic membrane market for repairing skin wounds. They are increasing their R&D efforts to study the safety and efficacy of HAAM for burn wounds and diabetic foot ulcers.

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The amniotic membrane market is highly consolidated in nature, with only four major players accounting for ~70% of the market share. Companies are increasing their presence in inorganic strategies such as commercializing their product portfolios. For instance, in August 2018, MiMedx - a leader in placental-based products, revealed that it had received regulatory approval to commercialize its product portfolio in dehydrated human amnion/chorion membrane (dHACM) products in Australia.

However, complications associated with amniotic membranes, such as post AM transplantation infection and premature degeneration, are likely to hamper market growth. To win over these hurdles, companies should increase R&D related to the orientation of AM with useful techniques such as sutureless AM in clinical-based setting.